

Alain Couvineau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8575660/publications.pdf>

Version: 2024-02-01

123
papers

4,882
citations

87888

38
h-index

98798

67
g-index

125
all docs

125
docs citations

125
times ranked

5362
citing authors

#	ARTICLE	IF	CITATIONS
1	Signal Transduction by VIP and PACAP Receptors. <i>Biomedicines</i> , 2022, 10, 406.	3.2	25
2	Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. <i>Molecules</i> , 2021, 26, 4849.	3.8	12
3	Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. <i>World Journal of Gastroenterology</i> , 2021, 27, 7582-7596.	3.3	14
4	Editorial: GPCR in Inflammatory and Cancer Diseases. <i>Frontiers in Endocrinology</i> , 2020, 11, 588157.	3.5	2
5	Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. <i>Frontiers in Endocrinology</i> , 2019, 10, 709.	3.5	41
6	Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation. <i>Journal of Neuroinflammation</i> , 2019, 16, 64.	7.2	32
7	Wide clinical spectrum in ALG8-CDG: clues from molecular findings suggest an explanation for a milder phenotype in the first-described patient. <i>Pediatric Research</i> , 2019, 85, 384-389.	2.3	8
8	Obesity-induced pancreatopathy in rats is reversible after bariatric surgery. <i>Scientific Reports</i> , 2018, 8, 16295.	3.3	18
9	The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. <i>Frontiers in Endocrinology</i> , 2018, 9, 573.	3.5	24
10	Ectopic expression of OX1R in ulcerative colitis mediates anti-inflammatory effect of orexin-A. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3618-3628.	3.8	25
11	<i>In vitro</i> , <i>in vivo</i> and <i>ex vivo</i> demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 6952-6967.	1.8	19
12	Vasoactive intestinal peptide dampens formyl-peptide-induced ROS production and inflammation by targeting a MAPK-p47phox phosphorylation pathway in monocytes. <i>Mucosal Immunology</i> , 2017, 10, 332-340.	6.0	19
13	Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome. <i>Journal of Hepatology</i> , 2017, 66, 930-941.	3.7	26
14	Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2017, 46, 631-638.	1.1	11
15	Impact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice. <i>PLoS ONE</i> , 2017, 12, e0169908.	2.5	23
16	Tu1498 The Hypothalamic Neuropeptide, Orexin, Prevents Chronic Pancreatitis in Cerulein Mice Model. <i>Gastroenterology</i> , 2016, 150, S917.	1.3	1
17	Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced <i>in vivo</i> cardiovascular side effects in a Parkinson's disease model. <i>Neuropharmacology</i> , 2016, 108, 440-450.	4.1	44
18	Abstract 4581: Combination treatment of orexin-A and NAB-paclitaxel in pancreas cancer: <i>in vitro</i> and <i>in vivo</i> studies. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
19	Functional Characterization of PRKAR1A Mutations Reveals a Unique Molecular Mechanism Causing Acrodysostosis but Multiple Mechanisms Causing Carney Complex. <i>Journal of Biological Chemistry</i> , 2015, 290, 27816-27828.	3.4	28
20	Crucial role of the orexinâ€B C-terminus in the induction of OX ₁ receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis. <i>British Journal of Pharmacology</i> , 2015, 172, 5211-5223.	5.4	19
21	Stimulatory effect of pituitary adenylate cyclase-activating polypeptide 6-38, M65 and vasoactive intestinal polypeptide 6-28 on trigeminal sensory neurons. <i>Neuroscience</i> , 2015, 308, 144-156.	2.3	19
22	Mo1684 Anti-Inflammatory Properties of the Neuropeptide Orexins in Ulcerative Colitis: A New Promising Therapeutical Molecule. <i>Gastroenterology</i> , 2015, 148, S-685.	1.3	0
23	The orexin type 1 receptor is overexpressed in advanced prostate cancer with a neuroendocrine differentiation, and mediates apoptosis. <i>European Journal of Cancer</i> , 2014, 50, 2126-2133.	2.8	31
24	Abstract 4214: Antitumoral effects of orexins and their receptors OX1R in pancreatic ductal adenocarcinomas (PDAC). , 2014, , .		0
25	Abstract 5299: The C-terminus of orexin plays a crucial role in the cellular apoptosis induction mediated by OX1 receptor. , 2014, , .		0
26	Sa2023 Importance of the Orexin-B C-Terminal End in the Cellular Apoptosis Induction Mediated by Ox1 Receptor. <i>Gastroenterology</i> , 2013, 144, S-361-S-362.	1.3	0
27	Sa2022 Orexins and Their Gpcr Receptors Ox1r: Antitumoral Effects in Pancreatic Adenocarcinomas. <i>Gastroenterology</i> , 2013, 144, S-361.	1.3	0
28	Strategies for Studying the Ligand Binding Site of GPCRs. <i>Methods in Enzymology</i> , 2013, 520, 219-237.	1.0	4
29	The VPAC1 receptor: structure and function of a class B GPCR prototype. <i>Frontiers in Endocrinology</i> , 2012, 3, 139.	3.5	19
30	Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction. <i>FASEB Journal</i> , 2012, 26, 2060-2071.	0.5	25
31	The Family B1 GPCR: Structural Aspects and Interaction with Accessory Proteins. <i>Current Drug Targets</i> , 2012, 13, 103-115.	2.1	51
32	Intestinal cell targeting of a stable recombinant Cuâ€Zn SOD from <i>Cucumis melo</i> fused to a gliadin peptide. <i>Journal of Biotechnology</i> , 2012, 159, 99-107.	3.8	4
33	Tu1834 Orexins Exert a PRO-Apoptotic Effect on Digestive Human Neuroendocrine Tumors (NET) in an Ex-Vivo Culture Model of Tissue Slices. <i>Gastroenterology</i> , 2012, 142, S-857.	1.3	0
34	VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. <i>British Journal of Pharmacology</i> , 2012, 166, 42-50.	5.4	95
35	Abstract 1215: Orexin and their 7-membrane spanning receptors OX1R: a new colon cancer therapeutic target. , 2012, , .		0
36	Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP. <i>Biochimie</i> , 2011, 93, 669-677.	2.6	23

#	ARTICLE	IF	CITATIONS
37	Recurrent <i>PRKAR1A</i> Mutation in Acrodysostosis with Hormone Resistance. <i>New England Journal of Medicine</i> , 2011, 364, 2218-2226.	27.0	162
38	VPAC1 receptor binding site: Contribution of photoaffinity labeling approach. <i>Neuropeptides</i> , 2010, 44, 127-132.	2.2	28
39	Subtle conformational changes between CX3CR1 genetic variants as revealed by resonance energy transfer assays. <i>FASEB Journal</i> , 2010, 24, 4585-4598.	0.5	12
40	Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-transmembrane spanning receptor: role in the orexin receptor OX1R-driven apoptosis. <i>FASEB Journal</i> , 2009, 23, 4069-4080.	0.5	48
41	Molecular and Conformational Determinants of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) for Activation of the PAC1 Receptor. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3308-3316.	6.4	76
42	Production and Purification of Large Quantities of the Functional N-Terminal Ectodomain of Human VPAC1 Receptor. <i>Journal of Molecular Neuroscience</i> , 2008, 36, 249-253.	2.3	4
43	The N-Terminal Parts of VIP and Antagonist PG97-269 Physically Interact with Different Regions of the Human VPAC1 Receptor. <i>Journal of Molecular Neuroscience</i> , 2008, 36, 245-248.	2.3	18
44	Biological and Structural Analysis of Truncated Analogs of PACAP27. <i>Journal of Molecular Neuroscience</i> , 2008, 36, 260-269.	2.3	25
45	Class-B GPCR activation: is ligand helix-capping the key?. <i>Trends in Biochemical Sciences</i> , 2008, 33, 314-319.	7.5	93
46	PACAP prevents toxicity induced by cisplatin in rat and primate neurons but not in proliferating ovary cells: Involvement of the mitochondrial apoptotic pathway. <i>Neurobiology of Disease</i> , 2008, 32, 66-80.	4.4	32
47	Novel stable PACAP analogs with potent activity towards the PAC1 receptor. <i>Peptides</i> , 2008, 29, 919-932.	2.4	109
48	PTHR1 mutations associated with Ollier disease result in receptor loss of function. <i>Human Molecular Genetics</i> , 2008, 17, 2766-2775.	2.9	103
49	The Vasoactive Intestinal Peptide (VIP) $\hat{\pm}$ -Helix Up to C Terminus Interacts with the N-Terminal Ectodomain of the Human VIP/Pituitary Adenylate Cyclase-Activating Peptide 1 Receptor: Photoaffinity, Molecular Modeling, and Dynamics. <i>Molecular Endocrinology</i> , 2008, 22, 147-155.	3.7	39
50	Class II G protein-coupled receptors for VIP and PACAP: Structure, models of activation and pharmacology. <i>Peptides</i> , 2007, 28, 1631-1639.	2.4	183
51	Involvement of VIP and PACAP in neonatal brain lesions generated by a combined excitotoxic/inflammatory challenge. <i>Peptides</i> , 2007, 28, 1727-1737.	2.4	20
52	Establishment of a CHO Cell Clone Stably Expressing the Recombinant Human VIP-1 Receptor. <i>Annals of the New York Academy of Sciences</i> , 2006, 805, 570-573.	3.8	1
53	Spatial Approximation between the C-Terminus of VIP and the N-Terminal Ectodomain of the VPAC1 Receptor. <i>Annals of the New York Academy of Sciences</i> , 2006, 1070, 180-184.	3.8	1
54	The Human VPAC1 Receptor: Identification of the N-terminal Ectodomain as a Major VIP-Binding Site by Photoaffinity Labeling and 3D Modeling. <i>Annals of the New York Academy of Sciences</i> , 2006, 1070, 205-209.	3.8	7

#	ARTICLE	IF	CITATIONS
55	Expression and GTP Sensitivity of Peptide Histidine Isoleucine High-Affinity-Binding Sites in Rat. <i>Annals of the New York Academy of Sciences</i> , 2006, 1070, 215-219.	3.8	1
56	Characterization of the New Photoaffinity Probe (Bz2-K24)-VIP. <i>Annals of the New York Academy of Sciences</i> , 2006, 1070, 575-580.	3.8	1
57	Peptide Agonist Docking in the N-terminal Ectodomain of a Class II G Protein-coupled Receptor, the VPAC1 Receptor. <i>Journal of Biological Chemistry</i> , 2006, 281, 12792-12798.	3.4	58
58	Diffuse Pharmacophoric Domains of Vasoactive Intestinal Peptide (VIP) and Further Insights into the Interaction of VIP with the N-terminal Ectodomain of Human VPAC1 Receptor by Photoaffinity Labeling with [Bpa6]-VIP. <i>Journal of Biological Chemistry</i> , 2004, 279, 38889-38894.	3.4	27
59	Presence of a N-terminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor. <i>Regulatory Peptides</i> , 2004, 123, 181-185.	1.9	23
60	Desensitization and internalization of human type 1 vasoactive intestinal peptide receptor (VPAC1) expressed in CHO cells. A mutagenesis study. <i>Gastroenterology</i> , 2003, 124, A466.	1.3	0
61	Serine 447 in the Carboxyl Tail of Human VPAC1 Receptor Is Crucial for Agonist-Induced Desensitization but Not Internalization of the Receptor. <i>Molecular Pharmacology</i> , 2003, 64, 1565-1574.	2.3	21
62	Photoaffinity Labeling Demonstrates Physical Contact between Vasoactive Intestinal Peptide and the N-terminal Ectodomain of the Human VPAC1 Receptor. <i>Journal of Biological Chemistry</i> , 2003, 278, 36531-36536.	3.4	42
63	Identification of Cytoplasmic Domains of hVPAC1 Receptor Required for Activation of Adenylyl Cyclase. <i>Journal of Biological Chemistry</i> , 2003, 278, 24759-24766.	3.4	45
64	Novel Receptor Partners and Function of Receptor Activity-modifying Proteins. <i>Journal of Biological Chemistry</i> , 2003, 278, 3293-3297.	3.4	283
65	Human VPAC1 Receptor Selectivity Filter. <i>Journal of Biological Chemistry</i> , 2002, 277, 37016-37022.	3.4	10
66	Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. <i>Regulatory Peptides</i> , 2002, 108, 165-173.	1.9	155
67	The Human VPAC1 Receptor. <i>Journal of Biological Chemistry</i> , 2001, 276, 10153-10160.	3.4	41
68	The human vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1) promoter: characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl.20. <i>Biochemical Journal</i> , 2000, 347, 623-632.	3.7	7
69	The human vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1) promoter: characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl.20. <i>Biochemical Journal</i> , 2000, 347, 623.	3.7	3
70	Identification of Key Residues for Interaction of Vasoactive Intestinal Peptide with Human VPAC1 and VPAC2 Receptors and Development of a Highly Selective VPAC1 Receptor Agonist. <i>Journal of Biological Chemistry</i> , 2000, 275, 24003-24012.	3.4	156
71	Tryptophan 67 in the Human VPAC1 Receptor: Crucial Role for VIP Binding. <i>Biochemical and Biophysical Research Communications</i> , 2000, 276, 654-659.	2.1	11
72	The Human Vasoactive Intestinal Peptide/Pituitary Adenylyl Cyclase Activating Peptide Receptor 1 (VPAC1): Constitutive Activation by Mutations at Threonine 343. <i>Biochemical and Biophysical Research Communications</i> , 1999, 254, 15-20.	2.1	19

#	ARTICLE	IF	CITATIONS
73	Receptors for Peptides of the VIP/PACAP and PYY/NPY/PP Families. , 1999, , 125-157.		14
74	Cloning and Functional Characterization of the Human VIP1/PACAP Receptor Promoter. Annals of the New York Academy of Sciences, 1998, 865, 59-63.	3.8	4
75	Site-Directed Mutagenesis of Human VIP1 versus VIP2 Receptors. Annals of the New York Academy of Sciences, 1998, 865, 378-381.	3.8	5
76	Constitutive Activation of the Human VIP1 Receptor. Annals of the New York Academy of Sciences, 1998, 865, 382-385.	3.8	3
77	Construction of Chimeras between Human VIP1 and Secretin Receptors: Identification of Receptor Domains Involved in Selectivity towards VIP, Secretin, and PACAP. Annals of the New York Academy of Sciences, 1998, 865, 386-389.	3.8	9
78	Constitutive activation of the human VIP1/PACAP receptor, a member of the new class II family of G protein-coupled receptors. Gastroenterology, 1998, 114, A1144.	1.3	0
79	A Homozygous Inactivating Mutation in the Parathyroid Hormone/Parathyroid Hormone-Related Peptide Receptor Causing Blomstrand Chondrodysplasia. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3373-3376.	3.6	171
80	Constitutive Activation of the Human Vasoactive Intestinal Peptide 1 Receptor, a Member of the New Class II Family of G Protein-coupled Receptors. Journal of Biological Chemistry, 1998, 273, 4990-4996.	3.4	61
81	Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia.. Journal of Clinical Investigation, 1998, 102, 34-40.	8.2	292
82	A Homozygous Inactivating Mutation in the Parathyroid Hormone/Parathyroid Hormone-Related Peptide Receptor Causing Blomstrand Chondrodysplasia. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3373-3376.	3.6	42
83	Aspartate 196 in the First Extracellular Loop of the Human VIP1 Receptor Is Essential for VIP Binding and VIP-Stimulated cAMP Production. Biochemical and Biophysical Research Communications, 1997, 230, 289-292.	2.1	40
84	Mutagenesis of N-Glycosylation Sites in the Human Vasoactive Intestinal Peptide 1 Receptor. Evidence That Asparagine 58 or 69 Is Crucial for Correct Delivery of the Receptor to Plasma Membrane. Biochemistry, 1996, 35, 1745-1752.	2.5	102
85	Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties. European Journal of Pharmacology, 1996, 302, 207-214.	3.5	23
86	G α i RNA Antisense Expression Demonstrates the Exclusive Coupling of Peptide YY Receptors to Gi2 Proteins in Renal Proximal Tubule Cells. Journal of Biological Chemistry, 1996, 271, 574-580.	3.4	24
87	Vasoactive Intestinal Peptide (VIP)1 Receptor. Journal of Biological Chemistry, 1996, 271, 12795-12800.	3.4	67
88	Receptors for VIP, PACAP, Secretin, GRF, Glucagon, GLP-1, and Other Members of Their New Family of G Protein-Linked Receptors: Structure-Function Relationship with Special Reference to the Human VIP-1 Receptor. Annals of the New York Academy of Sciences, 1996, 805, 94-109.	3.8	120
89	Mutagenesis of N-Glycosylation Sites in the Human VIP 1 Receptor. Annals of the New York Academy of Sciences, 1996, 805, 558-562.	3.8	1
90	Role of Cysteine Residues in the N-Terminal Extracellular Domain of the Human VIP 1 Receptor for Ligand Binding A Site-directed Mutagenesis Study. Annals of the New York Academy of Sciences, 1996, 805, 585-589.	3.8	6

#	ARTICLE	IF	CITATIONS
91	A Heterotrimeric G i3-protein Controls Autophagic Sequestration in the Human Colon Cancer Cell Line HT-29. <i>Journal of Biological Chemistry</i> , 1995, 270, 13-16.	3.4	106
92	Highly Conserved Aspartate 68, Tryptophane 73 and Glycine 109 in the N-Terminal Extracellular Domain of the Human VIP Receptor Are Essential for Its Ability to Bind VIP. <i>Biochemical and Biophysical Research Communications</i> , 1995, 206, 246-252.	2.1	95
93	Mutational Analysis of Cysteine Residues within the Extracellular Domains of the Human Vasoactive Intestinal Peptide (VIP) 1 Receptor Identifies Seven Mutants That Are Defective in VIP Binding. <i>Biochemical and Biophysical Research Communications</i> , 1995, 211, 901-908.	2.1	71
94	Localization and Processing of Glycosylphosphatidylinositol-Anchored Cathepsin D. <i>Biochemical and Biophysical Research Communications</i> , 1995, 211, 935-942.	2.1	2
95	G proteins in rat liver proliferation during cholestasis. <i>Hepatology</i> , 1994, 20, 1041-1047.	7.3	10
96	4 Receptors for gut regulatory peptides. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1994, 8, 77-110.	1.0	19
97	Human Intestinal VIP Receptor: Cloning and Functional Expression of Two cDNA Encoding Proteins with Different N-Terminal Domains. <i>Biochemical and Biophysical Research Communications</i> , 1994, 200, 769-776.	2.1	146
98	Neurotensin Receptor and Its mRNA Are Expressed in Many Human Colon Cancer Cell Lines But Not in Normal Colonic Epithelium: Binding Studies and RT-PCR Experiments. <i>Biochemical and Biophysical Research Communications</i> , 1994, 203, 465-471.	2.1	68
99	Regional Expression of Epithelial Dipeptidyl Peptidase IV in the Human Intestines. <i>Biochemical and Biophysical Research Communications</i> , 1994, 203, 1224-1229.	2.1	69
100	Synthesis of a Hydrophilic Affinity Matrix for the Purification of the Vasoactive Intestinal Peptide Receptor. <i>Analytical Biochemistry</i> , 1993, 211, 305-310.	2.4	7
101	Glycosylation of VIP receptors: A molecular basis for receptor heterogeneity. <i>Peptides</i> , 1993, 14, 483-489.	2.4	20
102	Characterization and distribution of alpha 2-adrenergic receptors in the human intestinal mucosa.. <i>Journal of Clinical Investigation</i> , 1993, 91, 2049-2057.	8.2	51
103	Common VIP / PACAP receptor in human small intestinal epithelium. <i>Regulatory Peptides</i> , 1992, 40, 242.	1.9	1
104	Solubilization and molecular characterization of active galanin receptors from rat brain. <i>Biochemistry</i> , 1992, 31, 2415-2422.	2.5	37
105	VIP receptors from porcine liver: High yield solubilization in a GTP-insensitive form. <i>Life Sciences</i> , 1991, 48, 135-141.	4.3	6
106	Functional and immunological evidence for stable association of solubilized vasoactive-intestinal-peptide receptor and stimulatory guanine-nucleotide-binding protein from rat liver. <i>FEBS Journal</i> , 1990, 187, 605-609.	0.2	29
107	Ac-Tyr1hGRF discriminates between VIP receptors from rat liver and intestinal epithelium. <i>Life Sciences</i> , 1989, 45, 829-833.	4.3	17
108	Solubilization of active VIP-receptor from porcine liver in a GTP-insensitive, G protein-free form. <i>Regulatory Peptides</i> , 1989, 26, 149.	1.9	0

#	ARTICLE	IF	CITATIONS
109	Interplay between VIP and PYY/NPY receptors during enterocytic differentiation along the crypt-villus axis in rat small intestine. <i>Regulatory Peptides</i> , 1989, 26, 183.	1.9	0
110	Solubilization of active and stable receptors for vasoactive intestinal peptide from rat liver. <i>Regulatory Peptides</i> , 1989, 25, 37-50.	1.9	13
111	Solubilization and hydrodynamic characterization of guanine nucleotide-sensitive vasoactive intestinal peptide-receptor complexes from rat intestine. <i>Biochemistry</i> , 1989, 28, 1667-1672.	2.5	18
112	Molecular Analysis of Vasoactive Intestinal Peptide Receptors: A Comparison with Receptors for VIP-Related Peptides. <i>Annals of the New York Academy of Sciences</i> , 1988, 527, 296-313.	3.8	52
113	Galanin Receptors in a Hamster Pancreatic \hat{I}^2 -Cell Tumor: Identification and Molecular Characterization. <i>Endocrinology</i> , 1987, 121, 284-289.	2.8	96
114	Phorbol ester induces loss of VIP stimulation of adenylate cyclase and VIP-binding sites in HT29 cells. <i>FEBS Letters</i> , 1987, 211, 151-154.	2.8	24
115	Molecular Characteristics and Peptide Specificity of Vasoactive Intestinal Peptide Receptors from Rat Cerebral Cortex. <i>Journal of Neurochemistry</i> , 1986, 47, 1469-1475.	3.9	35
116	Gastric inhibitory polypeptide receptor in hamster pancreatic beta cells. Direct cross-linking, solubilization and characterization as a glycoprotein. <i>FEBS Journal</i> , 1986, 159, 353-358.	0.2	22
117	Interaction of Peptide YY with Rat Intestinal Epithelial Plasma Membranes: Binding of the Radioiodinated Peptide. <i>Endocrinology</i> , 1986, 118, 1910-1917.	2.8	144
118	The Human Vasoactive Intestinal Peptide Receptor: Molecular Identification by Covalent Cross-Linking in Colonic Epithelium*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1985, 61, 50-55.	3.6	72
119	Interaction of PHM, PHI and 24-glutamine PHI with human VIP receptors from colonic epithelium: Comparison with rat intestinal receptors. <i>Life Sciences</i> , 1985, 36, 991-995.	4.3	33
120	Structural requirements for VIP interaction with specific receptors in human and rat intestinal membranes: Effect of nine partial sequences. <i>Biochemical and Biophysical Research Communications</i> , 1984, 121, 493-498.	2.1	75
121	The CIP receptor on pancreatic beta cell tumor: Molecular identification by covalent cross-linking. <i>Biochemical and Biophysical Research Communications</i> , 1984, 122, 283-288.	2.1	24
122	Gut Peptide Receptors and Signal Transduction in Intestinal Epithelium: State of the Art. <i>Frontiers of Gastrointestinal Research</i> , 0, , 21-33.	0.1	3
123	The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	7